Federal SB5059 amends the Public Health Service Act to streamline the review of biosimilar biological products.
Federal SB5059 proposes to amend the Public Health Service Act to streamline the review of biosimilar biological products. The bill specifically modifies Section 351(k)(5) by striking subparagraph (B) and redesignating subparagraph (C) as subparagraph (B). This change aims to expedite the approval process for biosimilars, which are biological products that are highly similar to already approved products. The streamlined review process is expected to enhance efficiency and accessibility for patients needing these products.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.